ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

被引：83

作者：

Kiavue, Nicolas ^{[1
]}

Cabel, Luc ^{[1
,2
]}

Melaabi, Samia ^{[1
]}

Bataillon, Guillaume ^{[1
]}

Callens, Celine ^{[1
]}

Lerebours, Florence ^{[1
]}

Pierga, Jean-Yves ^{[1
,3
]}

Bidard, Francois-Clement ^{[1
,2
]}

机构：

[1] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France

[2] Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France

[3] Paris Descartes Univ, Paris, France

来源：

ONCOGENE | 2020年 / 39卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; GENOMIC CHARACTERIZATION; BREAST; ACTIVATION; DOMAIN; TUMOR; HER3; LANDSCAPE;

D O I：

10.1038/s41388-019-1001-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.

引用

页码：487 / 502

页数：16

共 50 条

[1] ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Nicolas Kiavue
Luc Cabel
Samia Melaabi
Guillaume Bataillon
Celine Callens
Florence Lerebours
Jean-Yves Pierga
Francois-Clement Bidard
Oncogene, 2020, 39 : 487 - 502
[2] Frequency and function of ERBB3 mutations in bladder cancer
Hanrahan, Aphrothiti J.
Sfakianos, John P.
Ramirez, Ricardo
Kim, Phillip H.
Iyer, Gopa
Al-Ahmadie, Hikmat A.
Scott, Sasinya N.
Bajorin, Dean F.
Bochner, Bernard H.
Coleman, Jonathan A.
Rosenberg, Jonathan E.
Berger, Michael F.
Chandarlapaty, Sarat
Solit, David B.
CANCER RESEARCH, 2014, 74 (19)
[3] Screen for actionable ERBB3 mutations
Koivu, Marika K.
Chakroborty, Deepankar
Kurppa, Kari J.
Elenius, Klaus
CANCER RESEARCH, 2022, 82 (12)
[4] Oncogenic ERBB3 Mutations in Human Cancers
Jaiswal, Bijay S.
Kljavin, Noelyn M.
Stawiski, Eric W.
Chan, Emily
Parikh, Chaitali
Durinck, Steffen
Chaudhuri, Subhra
Pujara, Kanan
Guillory, Joseph
Edgar, Kyle A.
Janakiraman, Vasantharajan
Scholz, Rolf-Peter
Bowman, Krista K.
Lorenzo, Maria
Li, Hong
Wu, Jiansheng
Yuan, Wenlin
Peters, Brock A.
Kan, Zhengyan
Stinson, Jeremy
Mak, Michelle
Modrusan, Zora
Eigenbrot, Charles
Firestein, Ron
Stern, Howard M.
Rajalingam, Krishnaraj
Schaefer, Gabriele
Merchant, Mark A.
Sliwkowski, Mark X.
de Sauvage, Frederic J.
Seshagiri, Somasekar
CANCER CELL, 2013, 23 (05) : 603 - 617
[5] Screen for actionable ERBB3 mutations.
Koivu, Marika K.
Chakroborty, Deepankar
Kurppa, Kari J.
Elenius, Klaus
CANCER RESEARCH, 2021, 81 (13)
[6] Oncogenic ERBB3 mutations in human cancers
Jaiswal, Bijay S.
Kljavin, Noelyn M.
Stawiski, Eric
Durinck, Steffen
Chaudhuri, Subhra
Eigenbrot, Charles
Schaefer, Gabriele
de Sauvage, Frederic J.
Seshagiri, Somasekar
CANCER RESEARCH, 2014, 74 (19)
[7] PIK3CA mutations frequently coexist with PTEN mutations in endometrial cancer and overexpression of ERBB2 and/or ERBB3 in breast cancer
Oda, Katsutoshi
Stokoe, David
Timmerman, Luika
Jimbo, Takeshi
Okada, Jennifer
Taketani, Yuji
McCormick, Frank
CANCER RESEARCH, 2006, 66 (08)
[8] Targeting on ErbB3 for cancer therapy
Liu, Xifu
Li, Xingyan
Zhou, Mingdong
ACTA PHARMACOLOGICA SINICA, 2006, 27 : 8 - 8
[9] Trans-activating mutations of the pseudokinase ERBB3
Koivu, Marika K. A.
Chakroborty, Deepankar
Airenne, Tomi T.
Johnson, Mark S.
Kurppa, Kari J.
Elenius, Klaus
ONCOGENE, 2024, 43 (29) : 2253 - 2265
[10] Different Types of ERBB3 Mutations in Chinese NonSmall Cell Lung Cancer Patients
Wang, Q.
Xu, C.
Wang, W.
Wang, D.
Zhu, Y.
Zhuang, W.
Fang, M.
Wang, G.
Song, Y.
Lu, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1215 - S1215

← 1 2 3 4 5 →